Berberrubine inhibits Helicobacter pylori by inducing oxidative stress and impairing membrane integrity

References

[1] Díaz-Basabe A, Lattanzi G, Perillo F, Amoroso C, Baeri A, Farini A, et al. Porphyromonas gingivalis fuels colorectal cancer through CHI3L1-mediated iNKT cell-driven immune evasion. Gut Microbes. 2024; 16:2388801.

[2] Gao R, Kong C, Huang L, Li H, Qu X, Liu Z, et al. Mucosa-associated microbiota signature in colorectal cancer. Eur J Clin Microbiol Infect Dis. 2017; 36: 2073–2083.

[3] Liu X, Lu B, Tang H, Jia X, Zhou Q, Zeng Y, et al. Gut microbiome metabolites, molecular mimicry, and species-level variation drive long-term efficacy and adverse event outcomes in lung cancer survivors. EBioMedicine. 2024; 109:105427.

[4] Choi IJ, Kook MC, Kim YI, Cho SJ, Lee JY, Kim CG, et al. Helicobacter pylori therapy for the prevention of metachronous gastric cancer. N Engl J Med. 2018; 378: 1085–1095.

[5] Costa L, Corre S, Michel V, Le Luel K, Fernandes J, Ziveri J, et al. USF1 defect drives p53 degradation during Helicobacter pylori infection and accelerates gastric carcinogenesis. Gut. 2020; 69: 1582–1591.

[6] Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, et al. Helicobacter pylori infection and the risk of gastric-carcinoma. N Engl J Med. 1991; 325: 1127–1131.

[7] Molina-Infante J, Lucendo AJ, Angueira T, Rodriguez-Tellez M, Balboa A, Perez-Aisa A, et al. Optimized empiric triple and concomitant therapy for eradication in clinical practice: the OPTRICON study. Helicobacter. 2014; 19: 132.

[8] Gisbert JP, Calvet X. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. Aliment Pharmacol Ther. 2011; 34: 604–617.

[9] Megraud F, Gisbert JP. Towards effective empirical treatment for Helicobacter pylori eradication. Lancet. 2016; 388: 2325–2326.

[10] Vítor JMB, Vale FF. Alternative therapies for Helicobacter pylori: probiotics and phytomedicine. FEMS Immunol Med Microbiol. 2011; 63: 153–164.

[11] Stamatis G, Kyriazopoulos P, Golegou S, Basayiannis A, Skaltsas S, Skaltsa H. In vitro anti-Helicobacter pylori activity of Greek herbal medicines. J Ethnopharmacol. 2003; 88: 175–179.

[12] Bae EA, Han MJ, Kim NJ, Kim DH. Anti-Helicobacter pylori activity of herbal medicines. Biol Pharm Bull. 1998; 21: 990–992.

[13] Shi DH, Liu YW, Liu WW, Gu ZF. Inhibition of urease by extracts derived from 15 Chinese medicinal herbs. Pharm Biol. 2011; 49: 752–755.

[14] Song D, Hao J, Fan D. Biological properties and clinical applications of berberine. Front Med. 2020; 14: 564–582.

[15] Li C, Huang P, Wong K, Xu Y, Tan L, Chen H, et al. Coptisine-induced inhibition of Helicobacter pylori: elucidation of specific mechanisms by probing urease active site and its maturation process. J Enzyme Inhib Med Chem. 2018; 33: 1362–1375.

[16] Xiong RG, Huang SY, Wu SX, Zhou DD, Yang ZJ, Saimaiti A, et al. Anticancer effects and mechanisms of berberine from medicinal herbs: an update review. Molecules. 2022; 27: 4523.

[17] Kim HW, Lee JW, Yu AR, Yoon HS, Kang M, Lee BS, et al. Isoegomaketone exhibits potential as a new Mycobacterium abscessus inhibitor. Front Microbiol. 2024; 15:1344914.

[18] Sader HS, Fritsche TR, Jones RN. Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin. Antimicrob Agents Chemother. 2006; 50: 2330–2336.

[19] Liu Q, Tang Y, Jiang S, Yu X, Zhu H, Xie X, et al. Mechanisms of action of berberine hydrochloride in planktonic cells and biofilms of Pseudomonas aeruginosa. Microb Pathog. 2024; 193:106774.

[20] Alfei S, Schito GC, Schito AM, Zuccari G. Reactive oxygen species (ROS)-mediated antibacterial oxidative therapies: available methods to generate ros and a novel option proposal. Int J Mol Sci. 2024; 25: 7182.

RIGHTS & PERMISSIONS

2026 The Author(s). mLife published by John Wiley & Sons Australia, Ltd on behalf of Institute of Microbiology, Chinese Academy of Sciences.